Metformin treatment decreases microglial activation in the in vivo lps model of parkinson's disease.
Year: 2018
Type: dissertation
Abstract: Metformin is a widely used oral antidiabetic drug with known anti-inflammatory properties due to its action on AMP kinase. This drug has shown a protective effect on various brain tissues, including cortical neurons. However, the effect of metformin on the substantia nigra (SN), the main \nstructure affected in Parkinson’s disease (PD), has not yet been studied. Accumulating evidence suggest that inflammation may play a central role in the cell loss that occurs in PD. The aim of this work was to determine the effect of metformin on the microglial activation of the SN of rats using \nthe animal model of PD based on the injection of the pro-inflammogen lipopolysaccharide (LPS). In vivo and in vitro experiments were used to study the activation of microglia at both the cellular and molecular levels. Our results indicate that metformin overall inhibits microglia activation measured \nby OX-6 (MHCII marker), IKKβ (pro-inflammatory marker) and arginase (anti-inflammatory marker) immunoreactivity. In addition, qPCR experiments reveal that metformin treatment minimizes the expression levels of several pro- and anti-inflammatory cytokines. Furthermore, the drug decreases the phosphorylated forms of MAPKs as well as ROS generation through the \ninhibition of the NADPH oxidase enzyme. However, metformin treatment fails to protect the dopaminergic neurons of SN. These findings suggest that metformin could have both beneficial and harmful pharmacological effects and arise the question about the potential use of metformin for the \nprevention and treatment of PD.
Source: idUS (Universidad de Sevilla)
Author: Khadija Tayara
Institution: Universidad de Sevilla
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2903867859
